Ms. Wen Shi is currently the Regional General Manager of Sales and Marketing for Europe at Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (or “Hepalink”) where she leads the sales and marketing of Hepalink’s enoxaparin formulation products, business development, distributorship management as well as the company’s subsidiaries in overseas markets.

Ms. Shi has over 25 years of rich operational and managerial experience in the lifecycle management and business development of pharmaceutical and vaccine products.

Before joining Hepalink, Ms. Shi was Commercial Director at UK’s Mundi Pharma, where she oversaw the in-licensing of new products. Prior to that, during her time at Pfizer from 2011 to 2016, Ms. Shi served in a core leadership role for the launch of Prevenar 13 in adult indications at Pfizer’s European HQ. She led the successful launches of the product for two indications in the European market and received the Pfizer Global Award for her achievements.

Previously, Ms. Shi served in various global management positions at Sanofi Pasture and GSK having accumulated years of experience in the sales and marketing and business development for vaccine products.

Ms. Shi has a Master of Clinical Medicine degree from Shanghai Jiao Tong University School of Medicine, and an MBA from Reims Management School of France.